As of Sep 04
| +0.39 / +3.50%|
The 8 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 18.00, with a high estimate of 24.00 and a low estimate of 15.00. The median estimate represents a +56.25% increase from the last price of 11.52.
The current consensus among 9 polled investment analysts is to Buy stock in BioCryst Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.